Novo Ventures

About The Fund

Novo Ventures is a part of Novo Holdings, which serves as the holding and investment entity for the Novo Nordisk Foundation, recognized as one of the world's largest enterprise foundations. Novo Ventures focuses on investing in life science companies across various stages of development, ranging from seed to Series B investments. With a strong emphasis on the BioTech, FinTech, IoT, HealthTech, Material Science, Medical Devices, Healthcare, and Pharmaceutical industries, Novo Ventures aims to generate attractive long-term returns that contribute to the overall mission of improving public health and fostering sustainability in society and the environment. The fund's minimum investment begins at $100,000, with a maximum cap of $5,000,000, and their sweet spot lies around $1,500,000 per investment. By allocating significant direct investments and diversifying their capital investments, they maintain a diversified and robust portfolio, which includes equities, bonds, real estate, infrastructure assets, and private equity investments. Novo Holdings, including Novo Ventures, operates with the guiding principles of being value-driven, leading by example, nurturing talent, and striving for excellence in operations with a focus on generating strong financial returns and positive societal impact. Through responsible investing, they function as change catalysts, supporting companies that align with their aspiration of alleviating challenges facing human and planetary health. They have a geographical focus in North America, Europe, and Asia, managing an investment portfolio from offices in Copenhagen, London, San Francisco, Boston, Singapore, and Shanghai. The company finished the year 2023 with Total Assets under Management of 149 billion, achieving a 9.4% return on their Investment Portfolio, which underscores their effective strategy and commitment to being a leading responsible investor.